Literature DB >> 8956999

Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.

D Cosgrove1, D T Meehan, J A Grunkemeyer, J M Kornak, R Sayers, W J Hunter, G C Samuelson.   

Abstract

A mouse model for the autosomal form of Alport syndrome was produced. These mice develop a progressive glomerulonephritis with microhematuria and proteinuria, consistent with the human disease. End-stage renal disease develops at approximately 14 weeks of age. TEM analysis of the glomerular basement membranes (GBM) during development of renal pathology revealed focal multilaminated thickening and thinning beginning in the external capillary loops at 4 weeks and spreading throughout the GBM by 8 weeks. By 14 weeks, half of the glomeruli were fibrotic with collapsed capillaries. Immunofluorescence analysis of the GBM showed the absence of type IV collagen alpha-3, alpha-4, and alpha-5 chains and a persistence of alpha-1 and alpha-2 chains (these chains normally localize to the mesangial matrix). Northern blot analysis using probes specific for the collagen chains illustrate the absence of COL4A3 in the knockout, whereas mRNAs for the remaining chains are unchanged. An accumulation of fibronectin, heparan sulfate proteoglycan, laminin-1, and entactin was observed in the GBM of the affected animals. The temporal and spatial pattern of accumulation was consistent with that for thickening of the GBM as observed by TEM. Thus, expression of these basement membrane-associated proteins may be involved in the progression of Alport renal disease pathogenesis. The levels of mRNAs encoding the basement membrane-associated proteins at 7 weeks were unchanged.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956999     DOI: 10.1101/gad.10.23.2981

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  123 in total

1.  Alport syndrome with diffuse leiomyomatosis. When and when not?

Authors:  J H Miner
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

3.  Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly.

Authors:  Valerie LeBleu; Malin Sund; Hikaru Sugimoto; Gabriel Birrane; Keizo Kanasaki; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Heather McLaughlin; Charles F Shield; Raghu Kalluri
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

4.  Collagen XIII induced in vascular endothelium mediates alpha1beta1 integrin-dependent transmigration of monocytes in renal fibrosis.

Authors:  Jameel Dennis; Daniel T Meehan; Duane Delimont; Marisa Zallocchi; Greg A Perry; Stacie O'Brien; Hongmin Tu; Taina Pihlajaniemi; Dominic Cosgrove
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

5.  Models of chronic kidney disease.

Authors:  Hai-Chun Yang; Yiqin Zuo; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2010

6.  Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.

Authors:  Kyungmin Hahm; Matvey E Lukashev; Yi Luo; William J Yang; Brian M Dolinski; Paul H Weinreb; Kenneth J Simon; Li Chun Wang; Diane R Leone; Roy R Lobb; Donald J McCrann; Normand E Allaire; Gerald S Horan; Agnes Fogo; Raghu Kalluri; Charles F Shield; Dean Sheppard; Humphrey A Gardner; Shelia M Violette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 7.  Hematopoietic stem cells are pluripotent and not just "hematopoietic".

Authors:  Makio Ogawa; Amanda C LaRue; Meenal Mehrotra
Journal:  Blood Cells Mol Dis       Date:  2013-02-27       Impact factor: 3.039

8.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

9.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08

Review 10.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.